B and T Cell Reactivities After Immunization of Macaques with HIV Subcomponents
- 1 January 1988
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 4 (3) , 199-210
- https://doi.org/10.1089/aid.1988.4.199
Abstract
A model system was established for studies of humoral and cellular immunity to human immunodeficiency virus (HIV) antigens after vaccination. Macaques (Macaca fascicularis) were immunized with purified HIV, an infected cell extract rich in gp 120 or polypeptides of cloned genes representing parts of p24, gp41, and gp120. Western blot analysis best showed the appearance of antibodies to nucleocapsid proteins, and antibodies to higher molecular weight envelope glycoproteins were better demonstrated by radioimmunoprecipitation. With whole HIV, antibodies to p24 appeared first, and sometimes were the only ones to be demonstrable. Several immunizations with HIV or recombinant polypeptides were required to obtain antibodies to gp120, and the responses were weak. Although the envelope-specific response was weak, this was the only component that mediated neutralizing capacity. Escherichia coli-derived viral transmembrane polypeptide (g)p41 also had a poor immunizing effect. IgG synthesis from B cells in vitro was demonstrable to antigens and generally paralleled the antibody titers of sera after multiple immunizations. The HIV-specific lymphocyte proliferation response as measured by DNA synthesis was best seen with polypeptide p24-15, followed by the other antigens.This publication has 40 references indexed in Scilit:
- Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptorCell, 1987
- Site‐directed ELISA with synthetic peptides representing the HIV transmembrane glycoproteinJournal of Medical Virology, 1987
- T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia virusesNature, 1986
- Impaired Specific Cellular Response to HTLV-III before Other Immune Defects in Patients with HTLV-III InfectionNew England Journal of Medicine, 1986
- Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1986
- Restricted IgG Subclass Responses to HTLV-III/LAV and to Cytomegalovirus in Patients with AIDS and Lymphadenopathy SyndromeThe Journal of Infectious Diseases, 1986
- Human T-Cell Lymphotropic Virus Type III (HTLV-III) Core Antigens: Synthesis inEscherichia coliand Immunoreactivity with Human SeraDNA, 1986
- Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia coli-Derived Viral Antigenic PeptideBio/Technology, 1985
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983